Trial Profile
A Phase Ib/II Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 Oct 2021
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary) ; Lenalidomide (Primary) ; Obinutuzumab (Primary)
- Indications Follicular lymphoma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Roche
- 08 Jun 2021 Results of final analysis of Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory (R/R) follicular lymphoma presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 10 Dec 2020 Status changed from active, no longer recruiting to completed.
- 16 Jan 2020 Planned End Date changed from 10 Nov 2020 to 18 Sep 2020.